Familial Systemic Scleroderma

Studying familial forms of systemic scleroderma offers several advantages:

1. To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms); 2. To identify potential molecular markers predictive of disease progression; 3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Systemic Scleroderma Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Scleroderma, Systemic Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de Médecine interne et Immunologie clinique - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Aurélien GUFFROY, MD

CONTACT

[email protected]

33 3 69 5512 23

Aurélien GUFFROY, MD

PRINCIPAL_INVESTIGATOR

Jeannne MALLICK, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult subjects (≥ 18 years of age)
Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities
At least one first-degree relative with systemic scleroderma meeting the same criteria

Exclusion criteria

Subject who has expressed opposition to participating in the study

Treatment and study plan

Primary outcomes

Description of the clinical characteristics of patients with familial systemic scleroderma

Time frame: Up to 12 months

The clinical presentation describes how the disease manifests in patients:

the symptoms, their severity, and their progression.

Study contacts

Contact information is provided by the study sponsor or research team.

Aurélien GUFFROY, MD

CONTACT

[email protected]

33 3 69 5512 23

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: SCLERO

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Jan 15, 2026
Registry last updated: Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting